 | • レポートコード：MRC2-11QY03843 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はモノクローナル抗体(mAb)バイオシミラーのグローバル市場について調査・分析したレポートです。種類別（エリスロポエチン（EPO）、ヒト成長ホルモン（HGH）、顆粒球コロニー刺激因子（G-CSF）、モノクローナル抗体（mAb）、インスリン、インターフェロン（IFN）、その他）市場規模、用途別（抗がん、抗炎症・自己免疫）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別モノクローナル抗体(mAb)バイオシミラーの競争状況、市場シェア ・世界のモノクローナル抗体(mAb)バイオシミラー市場：種類別市場規模 2015年-2020年（エリスロポエチン（EPO）、ヒト成長ホルモン（HGH）、顆粒球コロニー刺激因子（G-CSF）、モノクローナル抗体（mAb）、インスリン、インターフェロン（IFN）、その他） ・世界のモノクローナル抗体(mAb)バイオシミラー市場：種類別市場規模予測 2021年-2026年（エリスロポエチン（EPO）、ヒト成長ホルモン（HGH）、顆粒球コロニー刺激因子（G-CSF）、モノクローナル抗体（mAb）、インスリン、インターフェロン（IFN）、その他） ・世界のモノクローナル抗体(mAb)バイオシミラー市場：用途別市場規模 2015年-2020年（抗がん、抗炎症・自己免疫） ・世界のモノクローナル抗体(mAb)バイオシミラー市場：用途別市場規模予測 2021年-2026年（抗がん、抗炎症・自己免疫） ・北米のモノクローナル抗体(mAb)バイオシミラー市場分析：米国、カナダ ・ヨーロッパのモノクローナル抗体(mAb)バイオシミラー市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのモノクローナル抗体(mAb)バイオシミラー市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のモノクローナル抗体(mAb)バイオシミラー市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのモノクローナル抗体(mAb)バイオシミラー市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Biocon、Celltrion、Dr. Reddy's Laboratories、Hospira、3SBio、Accord Healthcare、AET Biotech、Allergan、Amega Biotech、Others ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
Market Analysis and Insights: Global Monoclonal antibodies (mAbs) Biosimilars Market
The global Monoclonal antibodies (mAbs) Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Monoclonal antibodies (mAbs) Biosimilars Scope and Market Size
Monoclonal antibodies (mAbs) Biosimilars market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Monoclonal antibodies (mAbs) Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Biocon
Celltrion
Dr. Reddy’s Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Others
Market segment by Type, the product can be split into
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Market segment by Application, split into
Anti-Cancer
Anti-Inflammatory/Autoimmune
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
1.4 Market by Type
1.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Erythropoietin (EPO)
1.4.3 Human Growth Hormone (HGH)
1.4.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.4.5 Monoclonal Antibody (mAb)
1.4.6 Insulin
1.4.7 Interferon (IFN)
1.4.8 Others
1.5 Market by Application
1.5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2020 VS 2026
1.5.2 Anti-Cancer
1.5.3 Anti-Inflammatory/Autoimmune
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2015-2026)
2.2 Global Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Regions
2.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Share by Regions (2015-2020)
2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Monoclonal antibodies (mAbs) Biosimilars Market Growth Strategy
2.3.6 Primary Interviews with Key Monoclonal antibodies (mAbs) Biosimilars Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Market Size
3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2015-2020)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2015-2020)
3.1.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2019
3.3 Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.4 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.5 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2015-2020)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
6.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in North America (2019-2020)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
7.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Europe (2019-2020)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
8 China
8.1 China Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
8.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in China (2019-2020)
8.3 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
8.4 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
9 Japan
9.1 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
9.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Japan (2019-2020)
9.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
9.4 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
10.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
10.4 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
11 India
11.1 India Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
11.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in India (2019-2020)
11.3 India Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
11.4 India Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2020)
12.2 Monoclonal antibodies (mAbs) Biosimilars Key Players in Central & South America (2019-2020)
12.3 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
12.4 Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Biocon
13.1.1 Biocon Company Details
13.1.2 Biocon Business Overview
13.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
13.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020))
13.1.5 Biocon Recent Development
13.2 Celltrion
13.2.1 Celltrion Company Details
13.2.2 Celltrion Business Overview
13.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
13.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.2.5 Celltrion Recent Development
13.3 Dr. Reddy’s Laboratories
13.3.1 Dr. Reddy’s Laboratories Company Details
13.3.2 Dr. Reddy’s Laboratories Business Overview
13.3.3 Dr. Reddy’s Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
13.3.4 Dr. Reddy’s Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.3.5 Dr. Reddy’s Laboratories Recent Development
13.4 Hospira
13.4.1 Hospira Company Details
13.4.2 Hospira Business Overview
13.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
13.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.4.5 Hospira Recent Development
13.5 3SBio
13.5.1 3SBio Company Details
13.5.2 3SBio Business Overview
13.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
13.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.5.5 3SBio Recent Development
13.6 Accord Healthcare
13.6.1 Accord Healthcare Company Details
13.6.2 Accord Healthcare Business Overview
13.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
13.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.6.5 Accord Healthcare Recent Development
13.7 AET Biotech
13.7.1 AET Biotech Company Details
13.7.2 AET Biotech Business Overview
13.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
13.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.7.5 AET Biotech Recent Development
13.8 Allergan
13.8.1 Allergan Company Details
13.8.2 Allergan Business Overview
13.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
13.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.8.5 Allergan Recent Development
13.9 Amega Biotech
13.9.1 Amega Biotech Company Details
13.9.2 Amega Biotech Business Overview
13.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
13.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.9.5 Amega Biotech Recent Development
13.10 Others
13.10.1 Others Company Details
13.10.2 Others Business Overview
13.10.3 Others Monoclonal antibodies (mAbs) Biosimilars Introduction
13.10.4 Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
13.10.5 Others Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Monoclonal antibodies (mAbs) Biosimilars Key Market Segments
Table 2. Key Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
Table 3. Ranking of Global Top Monoclonal antibodies (mAbs) Biosimilars Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Erythropoietin (EPO)
Table 6. Key Players of Human Growth Hormone (HGH)
Table 7. Key Players of Granulocyte- Colony Stimulating Factor (G-CSF)
Table 8. Key Players of Monoclonal Antibody (mAb)
Table 9. Key Players of Insulin
Table 10. Key Players of Interferon (IFN)
Table 11. Key Players of Others
Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions (2015-2020)
Table 16. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Monoclonal antibodies (mAbs) Biosimilars Market Growth Strategy
Table 22. Main Points Interviewed from Key Monoclonal antibodies (mAbs) Biosimilars Players
Table 23. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2015-2020) (Million US$)
Table 24. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2015-2020)
Table 25. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2019)
Table 26. Global Monoclonal antibodies (mAbs) Biosimilars by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
Table 29. Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 32. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Share by Type (2015-2020)
Table 33. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2021-2026)
Table 34. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Share by Application (2015-2020)
Table 35. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 36. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Share by Application (2021-2026)
Table 37. North America Key Players Monoclonal antibodies (mAbs) Biosimilars Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Monoclonal antibodies (mAbs) Biosimilars Market Share (2019-2020)
Table 39. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 40. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2015-2020)
Table 41. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 42. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2015-2020)
Table 43. Europe Key Players Monoclonal antibodies (mAbs) Biosimilars Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Monoclonal antibodies (mAbs) Biosimilars Market Share (2019-2020)
Table 45. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2015-2020)
Table 47. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2015-2020)
Table 49. China Key Players Monoclonal antibodies (mAbs) Biosimilars Revenue (2019-2020) (Million US$)
Table 50. China Key Players Monoclonal antibodies (mAbs) Biosimilars Market Share (2019-2020)
Table 51. China Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 52. China Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2015-2020)
Table 53. China Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 54. China Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2015-2020)
Table 55. Japan Key Players Monoclonal antibodies (mAbs) Biosimilars Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Monoclonal antibodies (mAbs) Biosimilars Market Share (2019-2020)
Table 57. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2015-2020)
Table 59. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Monoclonal antibodies (mAbs) Biosimilars Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Monoclonal antibodies (mAbs) Biosimilars Market Share (2019-2020)
Table 63. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2015-2020)
Table 65. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2015-2020)
Table 67. India Key Players Monoclonal antibodies (mAbs) Biosimilars Revenue (2019-2020) (Million US$)
Table 68. India Key Players Monoclonal antibodies (mAbs) Biosimilars Market Share (2019-2020)
Table 69. India Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 70. India Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2015-2020)
Table 71. India Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 72. India Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Monoclonal antibodies (mAbs) Biosimilars Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Monoclonal antibodies (mAbs) Biosimilars Market Share (2019-2020)
Table 75. Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2015-2020)
Table 77. Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2015-2020)
Table 79. Biocon Company Details
Table 80. Biocon Business Overview
Table 81. Biocon Product
Table 82. Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 83. Biocon Recent Development
Table 84. Celltrion Company Details
Table 85. Celltrion Business Overview
Table 86. Celltrion Product
Table 87. Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 88. Celltrion Recent Development
Table 89. Dr. Reddy's Laboratories Company Details
Table 90. Dr. Reddy's Laboratories Business Overview
Table 91. Dr. Reddy's Laboratories Product
Table 92. Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 93. Dr. Reddy's Laboratories Recent Development
Table 94. Hospira Company Details
Table 95. Hospira Business Overview
Table 96. Hospira Product
Table 97. Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 98. Hospira Recent Development
Table 99. 3SBio Company Details
Table 100. 3SBio Business Overview
Table 101. 3SBio Product
Table 102. 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 103. 3SBio Recent Development
Table 104. Accord Healthcare Company Details
Table 105. Accord Healthcare Business Overview
Table 106. Accord Healthcare Product
Table 107. Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 108. Accord Healthcare Recent Development
Table 109. AET Biotech Company Details
Table 110. AET Biotech Business Overview
Table 111. AET Biotech Product
Table 112. AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 113. AET Biotech Recent Development
Table 114. Allergan Business Overview
Table 115. Allergan Product
Table 116. Allergan Company Details
Table 117. Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 118. Allergan Recent Development
Table 119. Amega Biotech Company Details
Table 120. Amega Biotech Business Overview
Table 121. Amega Biotech Product
Table 122. Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 123. Amega Biotech Recent Development
Table 124. Others Company Details
Table 125. Others Business Overview
Table 126. Others Product
Table 127. Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020) (Million US$)
Table 128. Others Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type: 2020 VS 2026
Figure 2. Erythropoietin (EPO) Features
Figure 3. Human Growth Hormone (HGH) Features
Figure 4. Granulocyte- Colony Stimulating Factor (G-CSF) Features
Figure 5. Monoclonal Antibody (mAb) Features
Figure 6. Insulin Features
Figure 7. Interferon (IFN) Features
Figure 8. Others Features
Figure 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2020 VS 2026
Figure 10. Anti-Cancer Case Studies
Figure 11. Anti-Inflammatory/Autoimmune Case Studies
Figure 12. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered
Figure 13. Global Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions: 2020 VS 2026
Figure 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players in 2019
Figure 18. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2019
Figure 20. North America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
乳癌モノクローナル抗体の世界市場（～2026年） Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protei…- G-CSFバイオシミラーの世界市場（～2026年） Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are…
- モノクローナル抗体療法の世界市場（～2026年） Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal ant…
- 癌治療用モノクローナル抗体の世界市場（～2026年） The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from oth…
- モノクローナル抗体ベース製品の世界市場（～2026年） Monoclonal antibody therapeutics is a type of immunotherapy in which monoclonal antibodies are used so that they can bind monospecifically to specific cells and proteins. This treatment stimulates the immune system of patients to attack the foreign cells which cause the disease. Monoclonal antibodie…